Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Subodh Verma

Showing results (431-440 of 616) with videos related to

Pageof 62
Sort By:
Circulation|March 14, 2018
Inflammatory and Cholesterol Risk in the FOURIER TrialErin A Bohula, Robert P Giugliano, Lawrence A Leiter, et al.
Current Opinion in Cardiology|June 26, 2021
Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?Abhinav Sharma, Haya Aziz, Subodh Verma, et al.
Journal of Clinical Medicine|July 27, 2024
Patient Reported Outcome Measures in Adults with Fontan Circulatory FailureGuillermo Agorrody, Isaac Begun, Subodh Verma, et al.
The Journal of Thoracic and Cardiovascular Surgery|September 24, 2015
Dual antiplatelet therapy use by Canadian cardiac surgeonsBobby Yanagawa, Marc Ruel, Christopher Bonneau, et al.
Circulation|December 20, 2018
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or StrokeSubodh Verma, Neil R Poulter, Deepak L Bhatt, et al.
European Heart Journal|March 4, 2025
Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trialMichael Böhm, Javed Butler, Andrew Coats, et al.
Journal of the American Society of Nephrology : JASN|October 18, 2017
Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac SurgeryMadhav Swaminathan, Mark Stafford-Smith, Glenn M Chertow, et al.
Circulation|December 7, 2023
Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical TrialsJohn J V McMurray, Kieran F Docherty, Rudolf A de Boer, et al.
JACC. Heart Failure|October 4, 2025
Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF ProgramBarry A Borlaug, Dalane W Kitzman, Shachi Patel, et al.
Circulation|July 21, 2004
TIMP-3 deficiency leads to dilated cardiomyopathyPaul W M Fedak, David S Smookler, Zamaneh Kassiri, et al.
Pageof 62

Showing results (431-440 of 616) with videos related to

Sort By:
Pageof 62
Circulation|March 14, 2018
Inflammatory and Cholesterol Risk in the FOURIER TrialErin A Bohula, Robert P Giugliano, Lawrence A Leiter, et al.
Current Opinion in Cardiology|June 26, 2021
Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?Abhinav Sharma, Haya Aziz, Subodh Verma, et al.
Journal of Clinical Medicine|July 27, 2024
Patient Reported Outcome Measures in Adults with Fontan Circulatory FailureGuillermo Agorrody, Isaac Begun, Subodh Verma, et al.
The Journal of Thoracic and Cardiovascular Surgery|September 24, 2015
Dual antiplatelet therapy use by Canadian cardiac surgeonsBobby Yanagawa, Marc Ruel, Christopher Bonneau, et al.
Circulation|December 20, 2018
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or StrokeSubodh Verma, Neil R Poulter, Deepak L Bhatt, et al.
European Heart Journal|March 4, 2025
Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trialMichael Böhm, Javed Butler, Andrew Coats, et al.
Journal of the American Society of Nephrology : JASN|October 18, 2017
Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac SurgeryMadhav Swaminathan, Mark Stafford-Smith, Glenn M Chertow, et al.
Circulation|December 7, 2023
Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical TrialsJohn J V McMurray, Kieran F Docherty, Rudolf A de Boer, et al.
JACC. Heart Failure|October 4, 2025
Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF ProgramBarry A Borlaug, Dalane W Kitzman, Shachi Patel, et al.
Circulation|July 21, 2004
TIMP-3 deficiency leads to dilated cardiomyopathyPaul W M Fedak, David S Smookler, Zamaneh Kassiri, et al.
Pageof 62